New weight loss drug IBIO-600 enters first human trial
NCT ID NCT07487376
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a single dose of the experimental drug IBIO-600 in 32 overweight or obese adults. The main goal is to see if the drug is safe and tolerable, and to measure how it moves through the body. Researchers will also look at its effect on body composition. This is a first step toward possibly developing a new weight management treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBIO-600
- What this could lead to
- If it works, this could point toward a new treatment for weight management in people who are overweight or obese.
- What could go wrong
- This is a very early Phase 1 trial with only 32 participants, so it's primarily checking safety, not effectiveness. The drug may not lead to meaningful weight loss or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Veritus Research
RECRUITINGBayswater, Victoria, 3153, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can patients power their own obesity research?
- Can antioxidant pills boost skin and blood carotenoids to improve cardiometabolic health?
- Could a daily probiotic help you feel fuller and eat less?
- Heart safety check for new Weight-Loss drug candidate
- Fasting plus fibre: a Gut-Boosting combo?
- AI health coach gives Real-Time weight loss tips via smartphone